Moreover, a retrospective analysis on biopsies from melanoma patients treated with pembrolizumab showed that PD-L1 positivity with a contemporary high percentage of CD8+ TILs in tumor tissue is associated with response [21]. Here, CD8A is linked to neoplasm.